RTR890

AssetAlso iHSC

Rejuvenated iPSC-derived haematopoietic stem cells for transplantation

Stage: Preclinical
Modality: Cell therapy
Target: Not known; 1
Indication: 0
Trials: 1
Developer

Indications

1

Blood disorders
Preclinical, retro.bio, 8 Oct 2026

In the full profile

Owner and partners1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.